• Angelini Ventures joined VectorY’s €74.5 million financing to advance therapies for ALS and other neurodegenerative diseases.
• VectorY develops vectorized antibody therapies and its own manufacturing platform for gene therapy delivery vehicles.
• The investment was made alongside the EIB through a co-investment facility.
• Lead candidate VTx-002 is being evaluated in the Phase 1/2 PIONEER-ALS study, expanded from 12 to 36 participants in September 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Angelini Ventures SpA published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.